Overview
Welcome to Immunicum's Investor Relations pages! Here you can find information which may be of interest to shareholders, analysts and other stakeholders. If you need more information or have any questions, please contact Alex Karlsson-Parra, INTERIM CEO.
Phone: +46(0)8 732 8400
Email: ir@immunicum.com
CEO statement, Q1 2020
“In February we were invited to present the updated data from the Phase II MERECA trial of ilixadencel in kidney cancer at the ASCO-SITC Clinical Immuno-Oncology Symposium. The updated data from the study showed that the combined treatment with ilixadencel demonstrated a nearly two-fold higher confirmed overall response rate as compared to sunitinib monotherapy. Furthermore survival data demonstrated a separation in survival curves in favor of the ilixadencel group without increased frequency or severity of side effects.”. – Alex Karlsson-Parra, interim CEO
To read the full report, please click here
Investor Downloads
